Certified Medication Aide Actual Exam Test Bank 1
Newest Complete Questions And Correct Detailed
Answers| Already Graded A+
1. A patient with a history of chronic kidney disease (CKD) stage 4 is prescribed a medication that
is primarily eliminated unchanged by the kidneys. The CMA notes that the patient has a low serum
albumin level. Which pharmacokinetic parameter is most significantly altered, and what is the
primary concern regarding drug therapy?
A. Increased volume of distribution due to decreased protein binding, leading to a higher risk of toxicity.
B. Decreased hepatic clearance due to reduced liver blood flow, requiring dose adjustment.
C. Enhanced renal excretion due to increased glomerular filtration rate, necessitating higher doses.
D. Prolonged half-life due to redistribution into adipose tissue, requiring extended dosing intervals.
Answer: A
Rationale: Low serum albumin reduces protein binding of drugs, increasing the free (active) fraction and
volume of distribution. In CKD, renal elimination is already impaired, so the combination of higher free
drug concentrations and reduced clearance significantly raises toxicity risk. Option B is incorrect
because hepatic clearance is not primarily affected. Option C is false because GFR is reduced in CKD.
Option D describes redistribution, which is less relevant than protein binding changes.
2. A CMA is reviewing a patient's medication administration record and notes that the patient is
receiving both warfarin and aspirin. The patient's INR is 3.5. Which of the following best describes
the pharmacodynamic interaction and the immediate priority action?
A. Additive anticoagulation effect; hold both medications and administer vitamin K.
B. Synergistic effect on platelet aggregation; continue both medications and recheck INR in 24 hours.
C. Antagonistic effect on vitamin K-dependent factors; increase warfarin dose.
D. Potentiation of warfarin via displacement from protein binding; reduce aspirin dose.
Answer: A
Rationale: Warfarin and aspirin have additive effects on hemostasis: warfarin inhibits clotting factor
synthesis, while aspirin inhibits platelet aggregation. An INR of 3.5 indicates supratherapeutic
anticoagulation, increasing bleeding risk. Immediate action is to hold both and consider vitamin K
reversal. Option B is dangerous; option C is opposite; option D describes a pharmacokinetic
interaction, but the primary issue is additive pharmacodynamics.
3. During a medication pass, a CMA discovers that a patient received a double dose of metoprolol
(a beta-blocker) due to a transcription error. The patient's vital signs are: heart rate 48 bpm, blood
pressure 82/50 mmHg. Which of the following is the most appropriate immediate intervention?
A. Administer atropine 0.5 mg IV push and prepare for transcutaneous pacing.
B. Administer glucagon 5 mg IV over 2 minutes.
Page 1
,C. Administer dopamine infusion at 5 mcg/kg/min.
D. Administer naloxone 0.4 mg IV push.
Answer: B
Rationale: Beta-blocker overdose causes bradycardia and hypotension. Glucagon is the specific antidote
because it stimulates adenylate cyclase independently of beta-receptors, increasing heart rate and
contractility. Atropine may be tried but is often ineffective in severe beta-blocker overdose. Dopamine
may be used but is not first-line. Naloxone is for opioid overdose.
4. A CMA is preparing to administer an oral liquid medication to a patient with a nasogastric (NG)
tube. The medication is a sustained-release formulation. Which of the following actions is most
appropriate?
A. Crush the tablet and mix with 30 mL of water before administering via NG tube.
B. Open the capsule and sprinkle the contents into the NG tube, then flush with 15 mL of water.
C. Contact the prescriber to request an immediate-release formulation.
D. Administer the medication via the NG tube as is, since it is a liquid.
Answer: C
Rationale: Sustained-release formulations should never be crushed or opened, as this can cause dose
dumping and toxicity. The CMA must contact the prescriber to change to an immediate-release
formulation or a liquid alternative that is safe for NG administration. Options A and B are unsafe.
Option D is incorrect because the medication is a liquid but still sustained-release, which may have
special properties; however, the key point is that sustained-release formulations should not be altered.
5. A patient receiving intravenous (IV) vancomycin develops red man syndrome shortly after the
infusion starts. The CMA should recognize that this reaction is most likely due to which of the
following mechanisms?
A. IgE-mediated type I hypersensitivity reaction to vancomycin.
B. Direct histamine release from mast cells and basophils.
C. Immune complex deposition in small blood vessels.
D. Delayed type IV hypersensitivity reaction.
Answer: B
Rationale: Red man syndrome is a non-immunologic, anaphylactoid reaction caused by rapid infusion of
vancomycin, leading to direct histamine release. It is not IgE-mediated (option A), not immune
complex-mediated (option C), and not delayed (option D). It can be prevented by slowing the infusion
rate and pre-treating with antihistamines if necessary.
6. A CMA is reviewing a patient's medication list and identifies a potential drug-drug interaction
between fluoxetine (a selective serotonin reuptake inhibitor) and linezolid (an oxazolidinone
antibiotic). Which of the following is the most serious potential adverse effect?
A. Hypertensive crisis due to increased norepinephrine.
B. Serotonin syndrome due to excessive serotonergic activity.
C. QT interval prolongation leading to torsades de pointes.
D. Bone marrow suppression due to additive myelotoxicity.
Page 2
,Answer: B
Rationale: Linezolid has weak monoamine oxidase inhibitor (MAOI) activity. Combined with an SSRI, it
can precipitate serotonin syndrome, characterized by agitation, hyperthermia, clonus, and autonomic
instability. Hypertensive crisis (option A) is more associated with MAOIs and tyramine. QT
prolongation (option C) is not a primary concern with this combination. Bone marrow suppression
(option D) is a risk with linezolid alone but not potentiated by fluoxetine.
7. A patient with a history of type 2 diabetes mellitus is prescribed pioglitazone. The CMA should
monitor for which of the following adverse effects, and what is the underlying mechanism?
A. Lactic acidosis due to inhibition of gluconeogenesis.
B. Weight gain and fluid retention due to PPAR-gamma activation.
C. Hypoglycemia due to increased insulin secretion.
D. Pancreatitis due to direct beta-cell toxicity.
Answer: B
Rationale: Pioglitazone is a thiazolidinedione that activates PPAR-gamma, improving insulin sensitivity
but also causing fluid retention and weight gain, which can exacerbate heart failure. Lactic acidosis
(option A) is associated with metformin. Hypoglycemia (option C) is uncommon with pioglitazone alone.
Pancreatitis (option D) is not a known adverse effect.
8. A CMA is preparing to administer a scheduled dose of digoxin to a patient. The patient's serum
potassium level is 3.2 mEq/L (low). Which of the following is the most appropriate action?
A. Administer the digoxin as ordered and monitor for bradycardia.
B. Hold the digoxin and notify the prescriber of the hypokalemia.
C. Administer the digoxin with a potassium supplement.
D. Administer half the dose of digoxin and recheck potassium in 4 hours.
Answer: B
Rationale: Hypokalemia potentiates digoxin toxicity by increasing the binding of digoxin to
Na+/K+-ATPase. The CMA should hold the digoxin and notify the prescriber to correct the potassium
level first. Administering digoxin in the presence of hypokalemia (option A) risks toxicity. Potassium
supplementation (option C) should be prescribed, not administered independently. Dose adjustment
(option D) is not appropriate without addressing the underlying electrolyte imbalance.
9. A patient is receiving an IV infusion of potassium chloride at 10 mEq/hour. The CMA notes that
the IV site is erythematous and the patient complains of pain. Which of the following is the most
appropriate immediate action?
A. Decrease the infusion rate to 5 mEq/hour.
B. Apply a warm compress to the site and continue the infusion.
C. Stop the infusion and assess for infiltration or phlebitis.
D. Flush the IV line with normal saline and restart at a different site.
Answer: C
Rationale: Pain and erythema at the IV site suggest phlebitis or infiltration, which can lead to tissue
necrosis if potassium extravasates. The infusion must be stopped immediately, and the site assessed.
Decreasing the rate (option A) does not address the local complication. Warm compress (option B) may
be used after discontinuing, but not while infusing. Flushing (option D) could worsen extravasation.
Page 3
, 10. A CMA is reviewing a patient's medication orders and sees that the patient is prescribed
enoxaparin 40 mg subcutaneously daily. The patient has an epidural catheter for postoperative
pain management. Which of the following is the most appropriate action?
A. Administer the enoxaparin as ordered, but monitor for signs of spinal hematoma.
B. Hold the enoxaparin and notify the prescriber because of the increased risk of spinal hematoma.
C. Administer the enoxaparin intramuscularly to reduce the risk of bleeding.
D. Administer the enoxaparin and ensure the epidural catheter is removed before the next dose.
Answer: B
Rationale: Concomitant use of anticoagulants like enoxaparin with epidural catheters significantly
increases the risk of spinal hematoma, which can lead to permanent paralysis. Guidelines recommend
holding anticoagulation until the epidural is removed and coagulation status is normalized. Option A is
unsafe. Option C is incorrect because enoxaparin should be given subcutaneously, not IM. Option D is
wrong because the epidural should be removed before starting anticoagulation, not after.
11. A medication aide is preparing to administer a controlled substance to a resident in a long-term
care facility. The medication is supplied in a multi-dose vial. The facility policy requires that any
discrepancy in controlled substance counts be reported immediately. During the count, the aide
notices that the number of doses remaining in the vial does not match the documentation. Which of
the following actions should the medication aide take first?
A. Administer the medication as ordered and document the discrepancy after the shift.
B. Notify the charge nurse immediately and withhold the medication until the discrepancy is resolved.
C. Adjust the count in the documentation to match the vial and proceed.
D. Discard the vial and obtain a new one from the pharmacy without reporting.
Answer: B
Rationale: The correct action is to notify the charge nurse immediately and withhold the medication until
the discrepancy is resolved. Controlled substance discrepancies must be reported promptly per legal and
facility policy to prevent diversion and ensure patient safety. Administering the medication (A) or
adjusting records (C) violates protocols and may lead to disciplinary action. Discarding the vial (D)
destroys evidence and is inappropriate.
12. A medication aide is reviewing a resident's medication administration record (MAR) and notes
that the resident is prescribed a transdermal fentanyl patch for chronic pain. The resident also has
a prescription for morphine sulfate immediate-release tablets for breakthrough pain. The aide is
aware that fentanyl is a high-alert medication. Which of the following considerations is most
critical when administering these medications?
A. Ensure the morphine is administered at least 30 minutes after applying the fentanyl patch to avoid
interaction.
B. Apply the fentanyl patch to a clean, dry, non-hairy area of the upper back and rotate sites.
C. Monitor the resident's respiratory rate before administering the morphine, as both drugs are respiratory
depressants.
D. Remove the old fentanyl patch before applying a new one, and discard it in a sharps container.
Answer: C
Rationale: The most critical consideration is monitoring respiratory rate before administering morphine
because both fentanyl and morphine are opioid agonists that can cause respiratory depression. Option C
Page 4
Newest Complete Questions And Correct Detailed
Answers| Already Graded A+
1. A patient with a history of chronic kidney disease (CKD) stage 4 is prescribed a medication that
is primarily eliminated unchanged by the kidneys. The CMA notes that the patient has a low serum
albumin level. Which pharmacokinetic parameter is most significantly altered, and what is the
primary concern regarding drug therapy?
A. Increased volume of distribution due to decreased protein binding, leading to a higher risk of toxicity.
B. Decreased hepatic clearance due to reduced liver blood flow, requiring dose adjustment.
C. Enhanced renal excretion due to increased glomerular filtration rate, necessitating higher doses.
D. Prolonged half-life due to redistribution into adipose tissue, requiring extended dosing intervals.
Answer: A
Rationale: Low serum albumin reduces protein binding of drugs, increasing the free (active) fraction and
volume of distribution. In CKD, renal elimination is already impaired, so the combination of higher free
drug concentrations and reduced clearance significantly raises toxicity risk. Option B is incorrect
because hepatic clearance is not primarily affected. Option C is false because GFR is reduced in CKD.
Option D describes redistribution, which is less relevant than protein binding changes.
2. A CMA is reviewing a patient's medication administration record and notes that the patient is
receiving both warfarin and aspirin. The patient's INR is 3.5. Which of the following best describes
the pharmacodynamic interaction and the immediate priority action?
A. Additive anticoagulation effect; hold both medications and administer vitamin K.
B. Synergistic effect on platelet aggregation; continue both medications and recheck INR in 24 hours.
C. Antagonistic effect on vitamin K-dependent factors; increase warfarin dose.
D. Potentiation of warfarin via displacement from protein binding; reduce aspirin dose.
Answer: A
Rationale: Warfarin and aspirin have additive effects on hemostasis: warfarin inhibits clotting factor
synthesis, while aspirin inhibits platelet aggregation. An INR of 3.5 indicates supratherapeutic
anticoagulation, increasing bleeding risk. Immediate action is to hold both and consider vitamin K
reversal. Option B is dangerous; option C is opposite; option D describes a pharmacokinetic
interaction, but the primary issue is additive pharmacodynamics.
3. During a medication pass, a CMA discovers that a patient received a double dose of metoprolol
(a beta-blocker) due to a transcription error. The patient's vital signs are: heart rate 48 bpm, blood
pressure 82/50 mmHg. Which of the following is the most appropriate immediate intervention?
A. Administer atropine 0.5 mg IV push and prepare for transcutaneous pacing.
B. Administer glucagon 5 mg IV over 2 minutes.
Page 1
,C. Administer dopamine infusion at 5 mcg/kg/min.
D. Administer naloxone 0.4 mg IV push.
Answer: B
Rationale: Beta-blocker overdose causes bradycardia and hypotension. Glucagon is the specific antidote
because it stimulates adenylate cyclase independently of beta-receptors, increasing heart rate and
contractility. Atropine may be tried but is often ineffective in severe beta-blocker overdose. Dopamine
may be used but is not first-line. Naloxone is for opioid overdose.
4. A CMA is preparing to administer an oral liquid medication to a patient with a nasogastric (NG)
tube. The medication is a sustained-release formulation. Which of the following actions is most
appropriate?
A. Crush the tablet and mix with 30 mL of water before administering via NG tube.
B. Open the capsule and sprinkle the contents into the NG tube, then flush with 15 mL of water.
C. Contact the prescriber to request an immediate-release formulation.
D. Administer the medication via the NG tube as is, since it is a liquid.
Answer: C
Rationale: Sustained-release formulations should never be crushed or opened, as this can cause dose
dumping and toxicity. The CMA must contact the prescriber to change to an immediate-release
formulation or a liquid alternative that is safe for NG administration. Options A and B are unsafe.
Option D is incorrect because the medication is a liquid but still sustained-release, which may have
special properties; however, the key point is that sustained-release formulations should not be altered.
5. A patient receiving intravenous (IV) vancomycin develops red man syndrome shortly after the
infusion starts. The CMA should recognize that this reaction is most likely due to which of the
following mechanisms?
A. IgE-mediated type I hypersensitivity reaction to vancomycin.
B. Direct histamine release from mast cells and basophils.
C. Immune complex deposition in small blood vessels.
D. Delayed type IV hypersensitivity reaction.
Answer: B
Rationale: Red man syndrome is a non-immunologic, anaphylactoid reaction caused by rapid infusion of
vancomycin, leading to direct histamine release. It is not IgE-mediated (option A), not immune
complex-mediated (option C), and not delayed (option D). It can be prevented by slowing the infusion
rate and pre-treating with antihistamines if necessary.
6. A CMA is reviewing a patient's medication list and identifies a potential drug-drug interaction
between fluoxetine (a selective serotonin reuptake inhibitor) and linezolid (an oxazolidinone
antibiotic). Which of the following is the most serious potential adverse effect?
A. Hypertensive crisis due to increased norepinephrine.
B. Serotonin syndrome due to excessive serotonergic activity.
C. QT interval prolongation leading to torsades de pointes.
D. Bone marrow suppression due to additive myelotoxicity.
Page 2
,Answer: B
Rationale: Linezolid has weak monoamine oxidase inhibitor (MAOI) activity. Combined with an SSRI, it
can precipitate serotonin syndrome, characterized by agitation, hyperthermia, clonus, and autonomic
instability. Hypertensive crisis (option A) is more associated with MAOIs and tyramine. QT
prolongation (option C) is not a primary concern with this combination. Bone marrow suppression
(option D) is a risk with linezolid alone but not potentiated by fluoxetine.
7. A patient with a history of type 2 diabetes mellitus is prescribed pioglitazone. The CMA should
monitor for which of the following adverse effects, and what is the underlying mechanism?
A. Lactic acidosis due to inhibition of gluconeogenesis.
B. Weight gain and fluid retention due to PPAR-gamma activation.
C. Hypoglycemia due to increased insulin secretion.
D. Pancreatitis due to direct beta-cell toxicity.
Answer: B
Rationale: Pioglitazone is a thiazolidinedione that activates PPAR-gamma, improving insulin sensitivity
but also causing fluid retention and weight gain, which can exacerbate heart failure. Lactic acidosis
(option A) is associated with metformin. Hypoglycemia (option C) is uncommon with pioglitazone alone.
Pancreatitis (option D) is not a known adverse effect.
8. A CMA is preparing to administer a scheduled dose of digoxin to a patient. The patient's serum
potassium level is 3.2 mEq/L (low). Which of the following is the most appropriate action?
A. Administer the digoxin as ordered and monitor for bradycardia.
B. Hold the digoxin and notify the prescriber of the hypokalemia.
C. Administer the digoxin with a potassium supplement.
D. Administer half the dose of digoxin and recheck potassium in 4 hours.
Answer: B
Rationale: Hypokalemia potentiates digoxin toxicity by increasing the binding of digoxin to
Na+/K+-ATPase. The CMA should hold the digoxin and notify the prescriber to correct the potassium
level first. Administering digoxin in the presence of hypokalemia (option A) risks toxicity. Potassium
supplementation (option C) should be prescribed, not administered independently. Dose adjustment
(option D) is not appropriate without addressing the underlying electrolyte imbalance.
9. A patient is receiving an IV infusion of potassium chloride at 10 mEq/hour. The CMA notes that
the IV site is erythematous and the patient complains of pain. Which of the following is the most
appropriate immediate action?
A. Decrease the infusion rate to 5 mEq/hour.
B. Apply a warm compress to the site and continue the infusion.
C. Stop the infusion and assess for infiltration or phlebitis.
D. Flush the IV line with normal saline and restart at a different site.
Answer: C
Rationale: Pain and erythema at the IV site suggest phlebitis or infiltration, which can lead to tissue
necrosis if potassium extravasates. The infusion must be stopped immediately, and the site assessed.
Decreasing the rate (option A) does not address the local complication. Warm compress (option B) may
be used after discontinuing, but not while infusing. Flushing (option D) could worsen extravasation.
Page 3
, 10. A CMA is reviewing a patient's medication orders and sees that the patient is prescribed
enoxaparin 40 mg subcutaneously daily. The patient has an epidural catheter for postoperative
pain management. Which of the following is the most appropriate action?
A. Administer the enoxaparin as ordered, but monitor for signs of spinal hematoma.
B. Hold the enoxaparin and notify the prescriber because of the increased risk of spinal hematoma.
C. Administer the enoxaparin intramuscularly to reduce the risk of bleeding.
D. Administer the enoxaparin and ensure the epidural catheter is removed before the next dose.
Answer: B
Rationale: Concomitant use of anticoagulants like enoxaparin with epidural catheters significantly
increases the risk of spinal hematoma, which can lead to permanent paralysis. Guidelines recommend
holding anticoagulation until the epidural is removed and coagulation status is normalized. Option A is
unsafe. Option C is incorrect because enoxaparin should be given subcutaneously, not IM. Option D is
wrong because the epidural should be removed before starting anticoagulation, not after.
11. A medication aide is preparing to administer a controlled substance to a resident in a long-term
care facility. The medication is supplied in a multi-dose vial. The facility policy requires that any
discrepancy in controlled substance counts be reported immediately. During the count, the aide
notices that the number of doses remaining in the vial does not match the documentation. Which of
the following actions should the medication aide take first?
A. Administer the medication as ordered and document the discrepancy after the shift.
B. Notify the charge nurse immediately and withhold the medication until the discrepancy is resolved.
C. Adjust the count in the documentation to match the vial and proceed.
D. Discard the vial and obtain a new one from the pharmacy without reporting.
Answer: B
Rationale: The correct action is to notify the charge nurse immediately and withhold the medication until
the discrepancy is resolved. Controlled substance discrepancies must be reported promptly per legal and
facility policy to prevent diversion and ensure patient safety. Administering the medication (A) or
adjusting records (C) violates protocols and may lead to disciplinary action. Discarding the vial (D)
destroys evidence and is inappropriate.
12. A medication aide is reviewing a resident's medication administration record (MAR) and notes
that the resident is prescribed a transdermal fentanyl patch for chronic pain. The resident also has
a prescription for morphine sulfate immediate-release tablets for breakthrough pain. The aide is
aware that fentanyl is a high-alert medication. Which of the following considerations is most
critical when administering these medications?
A. Ensure the morphine is administered at least 30 minutes after applying the fentanyl patch to avoid
interaction.
B. Apply the fentanyl patch to a clean, dry, non-hairy area of the upper back and rotate sites.
C. Monitor the resident's respiratory rate before administering the morphine, as both drugs are respiratory
depressants.
D. Remove the old fentanyl patch before applying a new one, and discard it in a sharps container.
Answer: C
Rationale: The most critical consideration is monitoring respiratory rate before administering morphine
because both fentanyl and morphine are opioid agonists that can cause respiratory depression. Option C
Page 4
